title: Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
abstract: BACKGROUND
  The prognosis of intraocular lymphoma (IOL) is poor, and the optimal treatment has not yet been defined. The study assesses ifosfamide (IFO) and trofosfamide (TRO) for treating IOL.
  
  
  METHODS
  We prospectively evaluated the efficacy and aqueous penetration of intravenous IFO, oral TRO and their active 4-hydroxy (4-OH) metabolites in 10 patients with IOL. Doses varied from 1500 to 2000 mg/m2/day on days 1-3 for IFO and from 150 to 400 mg/day (continuous or intermittent administration) for TRO. Four patients had newly diagnosed disease, and six had relapsed after pretreatment.
  
  
  RESULTS
  All patients responded to first treatment with IFO or TRO, and both of two patients responded to re-treatment with IFO on ocular relapse. Progression-free survival from the first treatment with IFO or TRO was > or = 6-18 months. In six of six patients, 4-OH metabolites were detected in the aqueous humor at a concentration of 0.32-1.56 microM immediately after IFO infusion with an aqueous/serum ratio of 0.19-0.54. 4-OH metabolites could be detected in one of three patients at a concentration of 7.2 microM 3-16 h after ingestion of TRO.
  
  
  CONCLUSIONS
  IFO and TRO are active in IOL. IOL patients evidence aqueous penetration of 4-OH metabolites after intravenous administration of IFO.
authors.affiliation: Department of Haematology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. kristoph.jahnke@charite.de
authors.forename: K
authors.initials: K
authors.lastname: Jahnke
authors.forename: T
authors.initials: T
authors.lastname: Wagner
authors.forename: N E
authors.initials: NE
authors.lastname: Bechrakis
authors.forename: G
authors.initials: G
authors.lastname: Willerding
authors.forename: S E
authors.initials: SE
authors.lastname: Coupland
authors.forename: L
authors.initials: L
authors.lastname: Fischer
authors.forename: E
authors.initials: E
authors.lastname: Thiel
authors.forename: A
authors.initials: A
authors.lastname: Korfel
mesh_terms: D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000493:pharmacokinetics*; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D018572:Disease-Free Survival; D005134:Eye Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007069:Ifosfamide / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D011446:Prospective Studies; D016879:Salvage Therapy
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; C003726:trofosfamide; D007069:Ifosfamide